clinical trial · NCT05497401
A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS
BonusBio Group Ltd·phase3·not yet recruiting·n = 300
ARDSMesenCurePlacebo
brief summary
The efficacy of the allogeneic cell-therapy product MesenCure in addition to standard of care will be evaluated in comparison to placebo control in 300 moderate to severe Covid patients
started
Apr 1, 2026
primary completion
Jun 1, 2028
completion
Oct 1, 2028
last updated
Aug 11, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol